Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post‐marketing surveillance

Nivolumab, a monoclonal antibody against human programmed death 1, was approved for the treatment of melanoma in July 2014 in Japan. Because the Japanese phase II studies (ONO‐4538‐02, ONO‐4538‐08) enrolled small numbers of melanoma patients, post‐marketing surveillance (PMS; JapicCTI‐163 272) was c...

Descripción completa

Detalles Bibliográficos
Autores principales: Uhara, Hisashi, Tsuchida, Tetsuya, Kiyohara, Yoshio, Akamatsu, Ayumi, Sakamoto, Takahiko, Yamazaki, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545090/
https://www.ncbi.nlm.nih.gov/pubmed/35607248
http://dx.doi.org/10.1111/1346-8138.16432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545090/
https://www.ncbi.nlm.nih.gov/pubmed/35607248
http://dx.doi.org/10.1111/1346-8138.16432

Ejemplares similares